

Substitute for form 1449B/PTO FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES AUGUST 30, 2007 SEP 04 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		FILING DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/RAZ/	A20	2004/0018177 A1	01-29-2004	Hill, <i>et al.</i>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
/RAZ/	B14	WO 01/21201 A2	03-29-2001	Isis Innovation Limited		
/RAZ/	B15	WO 01/085932 A3	11-15-2001	Aventis Pasteur Limited and Ludwig Institute for Cancer Research		
/RAZ/	B16	WO 02/068654 A3	09-06-2002	Centro de Ingenieria Genetica y Biotecnologia		
/RAZ/	B17	WO 2005/030964 A1	04-07-2005	Oxxon Therapeutics Limited		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/RAZ/	C186	"AIDS Vaccines Trials Dangerous," Isis News No. 11/12, Ho, M., ed., <i>Institute of Science in Society</i> [online], October 2001. Retrieved from the Internet, [retrieved on 2006]
/RAZ/	C187	Altman, J.D., and Feinberg, M.B., "HIV Escape: There and Back Again," <i>Nature Med.</i> 10(3): 229-230 (2004).
/RAZ/	C188	Borrow, P., <i>et al.</i> , "Virus-Specific CD8 ⁺ Cytotoxic T-Lymphocyte Activity Associated with Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Infection," <i>J. Virology</i> 68(9): 6103-6110 (1994).
/RAZ/	C189	Brander, C. and Walker, B.D., The HLA Class I Restricted CTL Response in HIV-1 Infection: Systematic Identification of Optimal Epitopes. HIV Molecular Immunology Database [online], February 2002 [retrieved on 2006-10-19], Retrieved from the Internet <URL:http://www.hiv-web.lanl.gov>.
/RAZ/	C190	Desrosiers, R.C., "Prospects for an AIDS Vaccine," <i>Nature Med.</i> 10(3):221-223 (2004).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES AUGUST 30, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		FILING DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/RAZ/	C191	Dose-Ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers [online], February 2007 [retrieved on 2007-03-07], Retrieved from the Internet <URL:http://www.clinicaltrials.gov>.
/RAZ/	C192	'Epitope Maps', HIV Molecular Immunology Database, [online] [Retrieved from the Internet on June 23, 2003]. <URL:http://hiv-web.lanl.gov/content/immunology/maps/maps.html.>
/RAZ/	C193	Fang, Z.-Y., <i>et al.</i> , "Expression of Vaccina E3L and K3L Genes by a Novel Recombinant Canarypox HIV Vaccine Vector Enhances HIV-1 Pseudovirion Production and Inhibits Apoptosis in Human Cells," <i>Virology</i> 291:272-284 (2001).
/RAZ/	C194	Friedrich, T.C., <i>et al.</i> , "Reversion of CTL Escape - Variant Immunodeficiency Viruses <i>in vivo</i> ," <i>Nature Med.</i> 10(3):275-281 (2004).
/RAZ/	C195	Hu, S.-L., "Non-Human Primate Models for AIDS Vaccine Research," <i>Curr. Drug Targets Infect. Disord.</i> , 5(2):193-201 (2005).
/RAZ/	C196	Kmiecniak, D., <i>et al.</i> , "Enhancement of Cellular and Humoral Immune Responses to Human Immunodeficiency Virus Type 1 Gag and Pol by a G/P-92 Fusion Protein Expressing Highly Immunogenic Gag p17/p24 and Pol p51 Antigens," <i>J. Hum. Virol.</i> 4(6):306-316(2001).
/RAZ/	C197	Koziel, M.J., "The Role of Immune Responses in the Pathogenesis of Hepatitis C Virus Infection," <i>J. Viral Hepatitis</i> 4(2):31-41 (1997). Abstract only provided.
/RAZ/	C198	Koziel, M.J. and Walker, B.D., "Characteristics of the Intrahepatic Cytotoxic T Lymphocyte Response in Chronic Hepatitis C Virus Infection," <i>Spriner Seminars in Immunopathology</i> , 19(1):69-83 (1997). Abstract only provided.
/RAZ/	C199	Leslie, A.J., <i>et al.</i> , "HIV Evolution: CTL Escape Mutation and Reversion After Transmission," <i>Nature Med.</i> 10(3):282-289 (2004).
/RAZ/	C200	Letvin, N.L., "Progress Toward an HIV Vaccine," <i>Annu. Rev. Med.</i> 56:213-223 (2005).
/RAZ/	C201	Matano, T., <i>et al.</i> , "Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques," <i>J. Virology</i> 72(1): 164-169 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES AUGUST 30, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		FILING DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/RAZ/	C202	Murata, K., <i>et al.</i> , "Characterization of <i>in Vivo</i> Primary and Secondary CD8 ⁺ T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses," <i>Cell. Immunol.</i> 173(1):96-107 (1996).
/RAZ/	C203	Niewiesk, S., <i>et al.</i> , "Measles Virus-Induced Immune Suppression in the Cotton Rat (<i>Sigmodon hispidus</i>) Model Depends on Viral Glycoproteins," <i>J. Virol.</i> 71(10):7214-7219 (1997).
/RAZ/	C204	Picard, O., <i>et al.</i> , "Complication of Intramuscular/Subcutaneous Immune Therapy in Severely Immune-compromised Individuals," <i>J. Acquir. Immune Defic. Syndr.</i> , 4(6):641-643 (1991).
/RAZ/	C205	Puig, M., <i>et al.</i> , "CD4+ Immune Escape and Subsequent T-Cell Failure Following Chimpanzee Immunization Against Hepatitis C Virus," <i>Hepatology</i> , 44:736-745 (2006).
/RAZ/	C206	Puls, R.L. and Emery, S., "Therapeutic Vaccination against HIV: Current Progress and Future Possibilities," <i>Clin. Sci.</i> , 110(1):59-71 (2006).
/RAZ/	C207	Riddell, S.R. and Greenberg, P.D., "Principles for Adoptive T Cell Therapy of Human Viral Diseases," <i>Annu. Rev. Immunol.</i> 13: 545-586 (1995).
/RAZ/	C208	Riddell, S.R., <i>et al.</i> "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones," <i>Science</i> 257 (1992).
/RAZ/	C209	Rowland-Jones, S., <i>et al.</i> , "HIV-specific Cytotoxic T-cells in HIV-exposed but Uninfected Gambian Women," <i>Nature Medicine</i> 1(1): 59-64 (1995).
/RAZ/	C210	Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults. National Institute of Allergy and Infectious Diseases [online], September 2006 [retrieved on 2007-03-07], Retrieved from the Internet <URL:http://www.clinicaltrials.gov>.
/RAZ/	C211	Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vector HIV Vaccine in Healthy Adults. National Institute of Allergy and Infectious Diseases [online], January 2007 [retrieved on 2007-03-01], Retrieved from the Internet <URL:http://www.clinicaltrials.gov>.
/RAZ/	C212	Smith, C.L., <i>et al.</i> , "Recombinant Modified Vaccinia Ankara Primes Functionally Activated CTL Specific for a Melanoma Tumor Antigen Epitope in Melanoma Patients with a High Risk of Disease Recurrence," <i>Int. J. Cancer</i> 113:259-266 (2005).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES AUGUST 30, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677
	FIRST NAMED INVENTOR Joerg Schneider		FILING DATE May 31, 2002
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/RAZ/	C213	Tartaglia, J., <i>et al.</i> , "Protection of Cats against Feline Leukemia Virus by Vaccination with a Canarypox Virus Recombinant, ALVAC-FL," <i>J. Virol.</i> 67(4):2370-2375 (1993).
/RAZ/	C214	Tascon, R.E., <i>et al.</i> , "Vaccination Against Tuberculosis by DNA Injection," <i>Nature Med.</i> 2(8):888-892 (1996).
/RAZ/	C215	Taylor, J. and Paoletti, E., "Fowlpox Virus as a Vector in Non-Avian Species," <i>Vaccine</i> 6:466-468 (1988).
/RAZ/	C216	Taylor, J., <i>et al.</i> , "Protective Immunity Against Avian Influenza Induced by Fowlpox Virus Recombinant," <i>Vaccine</i> 6:504-508 (1988).
/RAZ/	C217	Taylor, J., <i>et al.</i> , "Recombinant Fowlpox Virus Inducing Protective Immunity in Non-Avian Species," <i>Vaccine</i> 6(6):497-503 (1988).
/RAZ/	C218	Thomson, S.A., <i>et al.</i> , "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," <i>J. Immunol.</i> 160:1717-1723 (1998).
/RAZ/	C219	Thomson, S.A., <i>et al.</i> , "Recombinant Polyepitope Vaccines for the Delivery of Multiple CD8 Cytotoxic T Cell Epitopes," <i>J. Immunol.</i> , 157(2):822-826 (1996).
/RAZ/	C220	Tonini, T., <i>et al.</i> , "Current Approaches to Developing a Preventative HIV Vaccine," <i>Curr. Opin. Investig. Drugs</i> , 6(2):155-162 (2005).
/RAZ/	C221	Tsang, K.Y., <i>et al.</i> , "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," <i>J. Natl. Cancer Inst.</i> 87(13):982-990 (1995).
/RAZ/	C222	Tsuji, M., <i>et al.</i> , "CD4 ⁺ Cytolytic T Cell Clone Confers Protection Against Murine Malaria," <i>J. Exp. Med.</i> 172(5):1353-1357 (1990).
/RAZ/	C223	Tsukamoto, K., <i>et al.</i> , "Dual-Viral Vector Approach Induced Strong and Long-Lasting Protective Immunity against Very Virulent Infectious Bursal Disease Virus," <i>Virology</i> 269(2):257-267 (2000).
/RAZ/	C224	Van den Eynde, B. and Van der Bruggen, P., "Peptide Database," <i>Cancer Immunity</i> , March 2001, online, retrieved from the Internet on June 23, 2003. <URL: http://cancerimmunity.org/peptidedatabase/tcellepitopes.htm >

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES AUGUST 30, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3022.1004-000		APPLICATION NO. 10/088,677	
	FIRST NAMED INVENTOR Joerg Schneider		FILING DATE May 31, 2002	
	EXAMINER Robert A. Zeman	CONFIRMATION NO. 4825	GROUP 1645	

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
/RAZ/	C225	Walker, B.D., <i>et al.</i> , "Long-term Culture and Fine Specificity of Human Cytotoxic T-Lymphocyte Clones Reactive with Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci. USA</i> 86:9514-9518 (1989).
/RAZ/	C226	Wiley, J.A., <i>et al.</i> , "Production of Interferon- γ by Influenza Hemagglutinin-Specific CD8 Effector T Cells Influences the Development of Pulmonary Immunopathology," <i>Am. J. Pathol.</i> 158(1): 119-130 (2001).

EXAMINER /Robert Zeman/	DATE CONSIDERED 11/13/2007
--------------------------------	-----------------------------------